Posted by shellson2 on 16th of Jun 2025 at 01:11 pm
PACB--just something to file away--long term play. Obviously a
devasting and unmet disease. Can only hope they or anyone can make
progress with this asap.
Target ALS Chooses PacBio HiFi Sequencing to
Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made
freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2,
2025 /PRNewswire/ -- Target ALS, a nonprofit breaking
down barriers to amyotrophic lateral sclerosis (ALS) research, has
partnered with PacBio (NASDAQ:
PACB), a
leading provider of high-quality, highly accurate long read
sequencing platforms, to launch the largest global whole genome
sequencing initiative for ALS to date. By applying PacBio's HiFi
sequencing to more than 6,000 genomes from people with ALS and
healthy controls, the project aims to detect structural variants,
repeat expansions, and other hard-to-detect genetic features that
may underlie the disease. As part of the
ALS Global Research Initiative
(AGRI), all data will be openly shared via the
Target ALS Data Engine, removing
barriers to access and enabling researchers around the world to
uncover disease mechanisms and explore new pathways to
treatment.
Posted by shellson2 on 15th of Oct 2025 at 07:42 pm
had a decent day, up 9%, expanded volume.
FROM TODAY: Investing.com - Canaccord Genuity maintained its Buy
rating and $3.00 price target on
Pacific
Biosciences of California (NASDAQ:PACB)following the company’s
announcement of new sequencing technology. The stock has shown
strong momentum with a 25.2% gain over the past six months,
according to
InvestingProdata,
despite trading at a relatively high Price/Book multiple of
7.77x.
Pacific Biosciences unveiled its SPRQ-Nx sequencing chemistry
and consumables for the Revio and Vega platforms before market open
on Tuesday. The new chemistry is designed to work with multi-use
SMRT cells for the Revio system, enabling a nearly 40% reduction in
cost per 20x genome. This cost reduction initiative comes as
InvestingProdata
shows the company maintaining strong liquidity with a current ratio
of 6.92x, indicating sufficient resources to fund its development
programs.
The company plans to begin beta testing on Revio in November,
with full commercial launch scheduled for 2026. Pacific Biosciences
also intends to integrate SPRQ-Nx chemistry and 5hmC detection
capabilities for its Vega platform in 2026.
Canaccord Genuity noted that the lower cost profile enabled by
the new chemistry and multi-use SMRT cells could prove highly
beneficial in population genomics and clinical settings. The firm
highlighted that Pacific Biosciences’ multi-use SMRT cells maintain
output per run, while competitor Oxford Nanopore’s reusable flow
cells experience decreased output after each use.
The investment bank believes the new technology could improve
Pacific Biosciences’ competitive position, support margin expansion
toward 50%, and potentially help the company reach cash breakeven
by the end of 2027.
Posted by shellson2 on 3rd of Jul 2025 at 11:08 am
Volume today already exceeded 10day avg. I’ve been holding for a
long time awaiting a positive chunk of good news to finally get
this puppy going…we’ll see
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
PACB--just something to file away--long
Posted by shellson2 on 16th of Jun 2025 at 01:11 pm
PACB--just something to file away--long term play. Obviously a devasting and unmet disease. Can only hope they or anyone can make progress with this asap.
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the ALS Global Research Initiative (AGRI), all data will be openly shared via the Target ALS Data Engine, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment.
PACB—Trying to make a run
Posted by shellson2 on 28th of Jul 2025 at 01:48 pm
PACB—Trying to make a run at Feb high
PACB--repost from 7/28. Been on these
Posted by shellson2 on 3rd of Oct 2025 at 10:19 am
PACB--repost from 7/28.
Been on these guys what seems like forever. Chart is improving. I believe that 2026 will finally be their year--FDA news throughout the year.
had a decent day, up
Posted by shellson2 on 15th of Oct 2025 at 07:42 pm
had a decent day, up 9%, expanded volume.
FROM TODAY: Investing.com - Canaccord Genuity maintained its Buy rating and $3.00 price target on Pacific Biosciences of California (NASDAQ:PACB)following the company’s announcement of new sequencing technology. The stock has shown strong momentum with a 25.2% gain over the past six months, according to InvestingProdata, despite trading at a relatively high Price/Book multiple of 7.77x.
Pacific Biosciences unveiled its SPRQ-Nx sequencing chemistry and consumables for the Revio and Vega platforms before market open on Tuesday. The new chemistry is designed to work with multi-use SMRT cells for the Revio system, enabling a nearly 40% reduction in cost per 20x genome. This cost reduction initiative comes as InvestingProdata shows the company maintaining strong liquidity with a current ratio of 6.92x, indicating sufficient resources to fund its development programs.
The company plans to begin beta testing on Revio in November, with full commercial launch scheduled for 2026. Pacific Biosciences also intends to integrate SPRQ-Nx chemistry and 5hmC detection capabilities for its Vega platform in 2026.
Canaccord Genuity noted that the lower cost profile enabled by the new chemistry and multi-use SMRT cells could prove highly beneficial in population genomics and clinical settings. The firm highlighted that Pacific Biosciences’ multi-use SMRT cells maintain output per run, while competitor Oxford Nanopore’s reusable flow cells experience decreased output after each use.
The investment bank believes the new technology could improve Pacific Biosciences’ competitive position, support margin expansion toward 50%, and potentially help the company reach cash breakeven by the end of 2027.
PACB--good start to the day.
Posted by shellson2 on 31st of Oct 2025 at 09:51 am
PACB--good start to the day. Up 8% on heavy Volume. Report 11/5
nice. ARK investment for over
Posted by morton7 on 2nd of Nov 2025 at 11:10 am
nice. ARK investment for over 1 million shares
PACB reports on the 5th
Posted by shellson2 on 2nd of Nov 2025 at 03:48 pm
PACB reports on the 5th
PACB--These stubborn sons of beyotches
Posted by shellson2 on 21st of Nov 2025 at 01:38 pm
PACB--These stubborn sons of beyotches showing healthy volume today, stock up 14%. I'm sticking with them. 2026 is year of Genomics
Volume remains healthy again today.
Posted by shellson2 on 24th of Nov 2025 at 11:11 am
Volume remains healthy again today. Up 9% in price
What about MGX? That's acting
Posted by mastermind on 21st of Nov 2025 at 01:44 pm
What about MGX? That's acting like a dog lately. And would you include WGS in this category?
WGS has much potential, but
Posted by shellson2 on 21st of Nov 2025 at 01:49 pm
WGS has much potential, but so over valued (but has been for a while now). Get back on MGX. Big fan of TXG too
Powering ahead now
Posted by shellson2 on 31st of Oct 2025 at 10:44 am
Powering ahead now
10 day avg volume achieved
Posted by shellson2 on 31st of Oct 2025 at 11:18 am
10 day avg volume achieved already
nice look on weekly
Posted by kingpin15 on 15th of Oct 2025 at 07:43 pm
nice look on weekly
At 3 month high. I
Posted by shellson2 on 2nd of Jul 2025 at 02:05 pm
At 3 month high. I like the volume today
Volume today already exceeded 10day
Posted by shellson2 on 3rd of Jul 2025 at 11:08 am
Volume today already exceeded 10day avg. I’ve been holding for a long time awaiting a positive chunk of good news to finally get this puppy going…we’ll see